BioCentury | Sep 28, 2018
Clinical News

Innovent's PD-1 Inhibitor leads to 22.7% ORR in Phase Ib for NETs

...approved for NSCLC. Anti-PD-L1 antibody A167 from the Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. subsidiary of Sichuan Kelun Pharmaceutical Co. Ltd....
BioCentury | Sep 21, 2018
Clinical News

Innovent reports Chinese NET, NSCLC data for PD-1 mAb

...approved for NSCLC. Anti-PD-L1 antibody A167 from the Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. subsidiary of Sichuan Kelun Pharmaceutical Co. Ltd....
BioCentury | Aug 31, 2018
Financial News

Harbour BioMed raises $85M series B on heels of cancer deals

..."BeiGene Prices Hong Kong Listing" ). Kelun-Biotech is the small molecules and biologics-focused subsidiary of Sichuan Kelun Pharmaceutical Co. Ltd....
BioCentury | Aug 31, 2018
Company News

Harbour gets ex-China rights to Kelun's anti-PD-L1 mAb

...outside of the Greater China region. Kelun-Biotech is the small molecules and biologics-focused subsidiary of Sichuan Kelun Pharmaceutical Co. Ltd....
...Cancer Beat” ). Sichuan Kelun Pharmaceutical Co. Ltd. (SZSE:002422), Chengdu, China Harbour BioMed, Shanghai, China Business: Cancer Elizabeth S. Eaton Harbour BioMed Sichuan Kelun Pharmaceutical Co. Ltd. Programmed...
BioCentury | Aug 27, 2018
Financial News

Harbour BioMed raises $85M on heels of cancer deals

..."BeiGene Prices Hong Kong Listing" ). Kelun-Biotech is the small molecules and biologics-focused subsidiary of Sichuan Kelun Pharmaceutical Co. Ltd....
BioCentury | Aug 20, 2018
Company News

Harbour gets ex-China rights to Kelun's anti-PD-L1 mAb

...outside of the Greater China region. Kelun-Biotech is the small molecules and biologics-focused subsidiary of Sichuan Kelun Pharmaceutical Co. Ltd....
Items per page:
1 - 6 of 6
BioCentury | Sep 28, 2018
Clinical News

Innovent's PD-1 Inhibitor leads to 22.7% ORR in Phase Ib for NETs

...approved for NSCLC. Anti-PD-L1 antibody A167 from the Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. subsidiary of Sichuan Kelun Pharmaceutical Co. Ltd....
BioCentury | Sep 21, 2018
Clinical News

Innovent reports Chinese NET, NSCLC data for PD-1 mAb

...approved for NSCLC. Anti-PD-L1 antibody A167 from the Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. subsidiary of Sichuan Kelun Pharmaceutical Co. Ltd....
BioCentury | Aug 31, 2018
Financial News

Harbour BioMed raises $85M series B on heels of cancer deals

..."BeiGene Prices Hong Kong Listing" ). Kelun-Biotech is the small molecules and biologics-focused subsidiary of Sichuan Kelun Pharmaceutical Co. Ltd....
BioCentury | Aug 31, 2018
Company News

Harbour gets ex-China rights to Kelun's anti-PD-L1 mAb

...outside of the Greater China region. Kelun-Biotech is the small molecules and biologics-focused subsidiary of Sichuan Kelun Pharmaceutical Co. Ltd....
...Cancer Beat” ). Sichuan Kelun Pharmaceutical Co. Ltd. (SZSE:002422), Chengdu, China Harbour BioMed, Shanghai, China Business: Cancer Elizabeth S. Eaton Harbour BioMed Sichuan Kelun Pharmaceutical Co. Ltd. Programmed...
BioCentury | Aug 27, 2018
Financial News

Harbour BioMed raises $85M on heels of cancer deals

..."BeiGene Prices Hong Kong Listing" ). Kelun-Biotech is the small molecules and biologics-focused subsidiary of Sichuan Kelun Pharmaceutical Co. Ltd....
BioCentury | Aug 20, 2018
Company News

Harbour gets ex-China rights to Kelun's anti-PD-L1 mAb

...outside of the Greater China region. Kelun-Biotech is the small molecules and biologics-focused subsidiary of Sichuan Kelun Pharmaceutical Co. Ltd....
Items per page:
1 - 6 of 6